NATURAL-HISTORY OF MULTIPLE-SCLEROSIS

被引:209
作者
WEINSHENKER, BG
机构
关键词
D O I
10.1002/ana.410360704
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Multiple sclerosis (MS) is the most common idiopathic inflammatory disease of the central nervous system. The distinction between MS and other benign or fulminant inflammatory demyelinating disorders is based on quantitative, rather than qualitative, differences in chronicity and severity. Primary progressive MS may differ from relapsing-remitting MS in MRI lesion frequency, immunogenetic profile, responsiveness to immunosuppressive treatment, and histology. In 60% of patients, MS begins as a relapsing-remitting disease and evolves secondarily into a progressive neurological illness. Life expectancy is not substantially altered in patients with MS, particularly in the early years of the illness. The rate of suicide has been reported to be increased sevenfold in MS patients. Up to 40% of patients with attacks severe enough to render them nonambulatory may not recover. At 15 years from MS onset, 50% of patients are disabled to the point at which they at least require a cane to walk a half block. Early age at onset, female sex, relapsing-remitting course at onset, and perhaps optic neuritis or sensory symptoms at onset and relatively few attacks in the first two years are associated with a favorable course.
引用
收藏
页码:S6 / S11
页数:6
相关论文
共 35 条
[1]  
[Anonymous], 1990, ANN NEUROL, V27, P591
[2]   THE CLINICAL COURSE OF MULTIPLE-SCLEROSIS DURING PREGNANCY AND THE PUERPERIUM [J].
BIRK, K ;
FORD, C ;
SMELTZER, S ;
RYAN, D ;
MILLER, R ;
RUDICK, RA .
ARCHIVES OF NEUROLOGY, 1990, 47 (07) :738-742
[3]   A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, 2-CENTER, PILOT TRIAL OF COP 1 IN CHRONIC PROGRESSIVE MULTIPLE-SCLEROSIS [J].
BORNSTEIN, MB ;
MILLER, A ;
SLAGLE, S ;
WEITZMAN, M ;
DREXLER, E ;
KEILSON, M ;
SPADA, V ;
WEISS, W ;
APPEL, S ;
ROLAK, L ;
HARATI, Y ;
BROWN, S ;
ARNON, R ;
JACOBSOHN, I ;
TEITELBAUM, D ;
SELA, M .
NEUROLOGY, 1991, 41 (04) :533-539
[4]   FACTORS ASSOCIATED WITH A MALIGNANT OR BENIGN COURSE OF MULTIPLE-SCLEROSIS [J].
CLARK, VA ;
DETELS, R ;
VISSCHER, BR ;
VALDIVIEZO, NL ;
MALMGREN, RM ;
DUDLEY, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 248 (07) :856-860
[5]   FACTORS ASSOCIATED WITH A RAPID COURSE OF MULTIPLE-SCLEROSIS [J].
DETELS, R ;
CLARK, VA ;
VALDIVIEZO, NL ;
VISSCHER, BR ;
MALMGREN, RM ;
DUDLEY, JP .
ARCHIVES OF NEUROLOGY, 1982, 39 (06) :337-341
[6]   A PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-MASKED, VARIABLE DOSAGE, CLINICAL-TRIAL OF AZATHIOPRINE WITH AND WITHOUT METHYLPREDNISOLONE IN MULTIPLE-SCLEROSIS [J].
ELLISON, GW ;
MYERS, LW ;
MICKEY, MR ;
GRAVES, MC ;
TOURTELLOTTE, WW ;
SYNDULKO, K ;
HOLEVOETHOWSON, MI ;
LERNER, CD ;
FRANE, MV ;
PETTLERJENNINGS, P .
NEUROLOGY, 1989, 39 (08) :1018-1026
[7]   UNSUSPECTED MULTIPLE-SCLEROSIS [J].
GILBERT, JJ ;
SADLER, M .
ARCHIVES OF NEUROLOGY, 1983, 40 (09) :533-536
[8]   THE CLINICAL PROFILE OF MS IN AUSTRALIA - A COMPARISON BETWEEN MEDIUM-FREQUENCY AND HIGH-FREQUENCY PREVALENCE ZONES [J].
HAMMOND, SR ;
ENGLISH, D ;
DEWYTT, C ;
MAXWELL, IC ;
MILLINGEN, KS ;
STEWARTWYNNE, EG ;
MCLEOD, JG ;
MCCALL, MG .
NEUROLOGY, 1988, 38 (06) :980-986
[9]  
KIDD D, 1993, ANN NEUROL, V34, P308
[10]  
KURTZKE JF, 1973, ACTA NEUROL SCAND, V49, P379